am I the only one who found Mounjaro harder than the injections
The title is the whole question — am I the only one who found Mounjaro harder than the injections — but here is why I am asking.
The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.
Went 10 to 12.5 on the calendar and had the worst fortnight of the whole run. Dropped back to 10 and everything settled.
14kg over 55 weeks, never went past 10mg, and constipation stayed mild the whole way. Posting because the loud threads are all 15mg.
Tell me where this is wrong. That is the useful part of posting it.
best — the order this archive was captured in
The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.
Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.
the trials titrated on a calendar, real people titrate on symptoms
Have you held a step for longer than the four-week minimum at any point?
Which week did the appetite change actually land for you?
What is the waist doing? That is usually the number still moving during a scale stall.
Pen or vial? The step sizes available differ and it changes this answer.
It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.
The step schedule question, answered properly, because it comes up weekly.
The label sets a minimum interval of four weeks between increases. That is a floor on how fast you may go, and it exists because tolerability, not efficacy, is what limits most people. There is nothing in the pharmacology that says you must increase at four weeks, or at eight, or ever.
What decides it in practice is whether the effect you want is still there. If appetite is quiet and the trend is going the right way, the dose is doing its job. If both have genuinely gone flat for six weeks or more, that is a conversation worth having with someone who knows your history.
sulphur burps are the signature complaint and they are not dangerous
Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.
Came off sema and onto tirz with a two-week gap. The first month was flat and I assumed I had made a mistake. Month two it moved.
Came off sema and onto tirz with a two-week gap.
Saving this one. It is the clearest statement of the stall problem I have read here.
Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.
On comparing yourself with the trial number.
SURMOUNT-1 reported roughly 21% mean body weight change at 72 weeks on the highest arm. Three things get dropped every time that figure is quoted here. It is a mean, and the distribution around it is very wide. It is 72 weeks, which is a year and a half. And it is a trial population with trial support, which is not the same as a person with a spreadsheet.
Use it as a rough shape, not a benchmark. A 12% year is inside the ordinary range and people quit over it every week on this board.
SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.
The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.
I would separate the two claims. That the GIP arm exists is uncontroversial; that it explains your muscle cramps pattern is a guess.
Push back: "gentler than sema" is a population statement. Plenty of people on this board have the opposite experience and they are not doing it wrong.
switching from sema is not a dose conversion, there is no clean equivalence
zepbound and mounjaro are the same compound with different labels
Week 29 was the first time the scale moved after a five-week stall. I changed nothing in that window.
That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.
Careful with "everyone tolerates it better". The people it did not suit stop posting, which makes this board look calmer than the drug is.
Disagree with the conversion table. There is no validated equivalence between the two molecules and posting one as though there is does real damage.
Not sure that follows. You went up a step and changed your training in the same fortnight.
Agree. The GIP component is the interesting half and it barely gets discussed outside c/glp1science.
Correction to my own post above — I said 2.5mg and I have been on 5mg since the spring. Same argument, wrong number.
a lot of people plateau nicely at 10mg and never need 15
- 1The distribution matters more than the mean. In the trial population the…7 comments in this branch · started by u/cormac_pereira
- 2It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part…6 comments in this branch · started by u/aurel_lindqvist